Mucosal Associated Invariant T Cell During Viral Pneumonia and Acute Respiratory Distress Syndrome

NCT06720818 · tracked via the Priya Life Science France tracker

Sponsor

University Hospital, Tours

Phase

Observational

Started

2025-05-05

Last updated

2025-05-29

Condition(s) studied

Viral PneumoniaAcute Respiratory Distress Syndrome (ARDS)

Study summary

Viral pneumonia, including SARS-CoV-2 and influenza A virus (IAV), can culminate in acute respiratory distress syndrome (ARDS), a severe form of respiratory failure with high mortality. Uncontrolled local inflammatory response and impaired tissue repair are hallmarks of ARDS. However, lack of in-depth understanding of the immunopathology lead to limited identification of potential 'endotypes' who may benefit from individualized targeted therapies. Mucosal Associated Invariant T (MAIT) cells represent a peculiar lineage of T cells with a wide panel of effector functions. Thus, they emerge as potential key players and appealing targets in ARDS through their potent abilities to modulate immune response at barrier sites and promote tissue repair. Recent data from the investigators and others indicated that MAIT cells are highly activated in patients with Sars-Cov-2 and IAV ARDS, but the associated activation mechanisms and precise functions remain unknown.

In this context, the investigators aim at investigating the implication and potential harnessing of MAIT cells in severe viral pneumonias and associated ARDS by with a dedicated clinical study. First, the investigators will perform a comprehensive and longitudinal phenotyping of immune response during viral pneumonia-induced ARDS, including MAIT cells, in blood -and airway compartment for mechanically ventilated patients. To provide more insight into specificity of virally induced pneumonia and ARDS, longitudinal phenotyping of immune response of patients with bacterial pneumonia, and control patients with unrelated ARDS (severe trauma, pancreatitis or major surgery) will also be performed.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Age ≥ 18 years * Patients admitted to critical care (Intensive Care Unit, Continuous Monitoring Unit, Intensive Care Unit) at the CHRU de Tours * Patients admitted to critical care for one of the following reasons: * Acute community-acquired pulmonary infection (pneumonia), * Severe acute pancreatitis, with onset of ARDS criteria less than 48 hours ago, * Severe isolated head injury requiring invasive mechanical ventilation, * Severe burn defined by a burned surface area exceeding 20% and/or deep lesions exceeding 3% of the total body surface area, with the onset of ARDS criteria less than 48 hours ago, * Patient admitted to Intensive Care Medicine, requiring invasive mechanical ventilation, * Patient admitted to cardiac surgery for scheduled surgery for valve replacement and/or coronary artery bypass grafting, with inclusion the day before surgery, Non-inclusion criteria : * Patients with severe immunosuppression (impairing the ability to analyse the immune response, particularly T lymphocytes): active haematological malignancy, solid organ transplantation or bone marrow transplantation, systemic immunosuppressive treatment, ongoing chemotherapy (including immune checkpoint inhibitors). * Person who has objected to data processing * Patient under guardianship or curatorship

Primary outcome measure(s)

MAIT cells frequency during pneumonia and ARDS — Blood and airway (tracheal aspiration or bronchoalveolar lavage, for patients under mechanical ventilation) will be sampled and analyzed at inclusion, day 3, day 5 and every week until ICU discharge (with a maximum of 90 days in ICU after inclusion)
MAIT cell frequency will be determined as % of CD3+ cells using flow cytometry techniques on biological samples obtained from samples done during routine care of patients included in the study (blood samples, and tracheal aspiration and broncho alveolar lavage for mechanically ventilated patients).

Trial sites (1)

Facility	City	Region	Status
University hospital	Tours	France	Recruiting

More University Hospital, Tours trials in France

Impact of Sound Shower Music Diffusion on Family Anxiety in Intensive Care Unit Waiting Room Starting soon

Apneic Oxygenation With High-flow Nasal Oxygenation After Preoxygenation With Noninvasive Ventilation Before Intubation in Hypoxemic Patients in Intensive Care Unit. Starting soon

Multiomics Approach in Adult Patients With Phenylketonuria Recruiting

Prospective Validation of a Pharmacological Biomarker for Low-Dose Rituximab in Rheumatoid Arthritis Recruiting

Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial Starting soon

Other trials for the same condition

Study of the Immunological Pathophysiological Mechanisms Associated With Acute Respiratory Distress Syndrome Recruiting

Assessment of the Reproducibility of the Recruitment-to-inflation Ratio (R/I Ratio) Measurement in Patients With Acute Respiratory Distress Syndrome Starting soon

Assessment of the PEEP Responsiveness to Titrate End-expiratory Pressure and of the Need for Muscle Relaxation During Prone Positioning in Moderate-to-severe Acute Respiratory Distress Syndrome: A Master Protocol Recruiting

Pulmonary Overdistension Assessment With Electrical Impedance Tomography in Patients With Acute Respiratory Distress Syndrom in Prone Position. Recruiting

Relationship Between the Level of Positive End-expiratory Pressure and Venous Congestion During Acute Respiratory Distress Syndrome. Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06720818 on ClinicalTrials.gov ↗ ← All trials in France